CorWave Appoints Magalie Durrèche as Chief Financial Officer

CorWave, a French company developing and manufacturing innovative cardiac assist devices, announces the appointment of Magalie Durrèche as Chief Financial Officer. Magalie Durrèche has over twenty years of experience in corporate finance, mainly in the industrial sector, which will be a major asset for the development of CorWave.

Before joining CorWave, Magalie Durrèche served as the Chief Financial Officer, Aftersales & Circular Economy, for the entire Stellantis group, an automotive company with a net revenue of €179.6 billion (2022) and industrial operations in more than 30 countries. After graduating from Neoma Business School, she began her career in financial auditing at PwC before joining the Financial Consolidation teams at Sodexo. She later joined the automotive manufacturer PSA, where she held various positions within the financial department between 2008 and 2015, providing her with a 360-degree view of the group’s various activities (Research and Development, Production and Industrial Partnerships, Sales, Financing, etc.). In 2015, she was appointed Head of Investor Relations and took part in the rollout of PSA Group’s profitable growth plan “Push to Pass” to financial markets. She was promoted in 2017 to Chief Financial Officer of PSA Bank (now Stellantis Financial Services), a group operating in 14 countries and generating over €1.5 billion in net banking income. In early 2020, she became Director of Consolidation and Financial Reporting and joined the project team for the merger between PSA and FCA (Fiat Chrysler Automobiles). She thus actively contributed to the formation of the New York Stock Exchange (NYSE)-listed Stellantis Group.

Magalie Durrèche will oversee the financial management and participate in the strategic planning and fundraising of CorWave, a company developing and manufacturing a blood pump based on breakthrough technology. She succeeds Zina Hamoumi, who served as Chief Financial Officer for five years before deciding to focus on other projects.

Magalie Durrèche, Chief Financial Officer of CorWave, states: “I am very pleased to join CorWave and to participate in its transformation into an industrial company in the clinical phase and then in the commercial phase. CorWave is at a pivotal time, having recently completed a second closing of its Series C and preparing to inaugurate its industrial site.”

“I am thrilled to welcome Magalie as Chief Financial Officer” comments Louis de Lillers, Chief Executive Officer of CorWave. “She brings solid experience, having held very high responsibilities within Stellantis, an industrial group of international scale. Endowed with a deep entrepreneurial mindset, Magalie will contribute to transforming CorWave into a global leader in cardiac assist devices. Her knowledge of the European and American financial markets, along with her experience with ESG (Environmental, Social, and Governance) matters, will be valuable assets for our upcoming growth phases. I would also like to warmly thank Zina Hamoumi who has greatly contributed to the development of CorWave in recent years.”

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.